From what I can tell, this is a humble, curious, and well-meaning guy that funds his menagerie of research interests with a successful tutoring business (a noble career in and of itself). I see absolutely no need to frame him as an unworthy crank.
From what I can tell, this is a humble, curious, and well-meaning guy that funds his menagerie of research interests with a successful tutoring business (a noble career in and of itself). I see absolutely no need to frame him as an unworthy crank.
> So, first of all, the confession: I’m not a neutral observer here. In talking about this paper, I’m talking my own book. My company, Highway Pharmaceuticals, is currently raising funds to get a safer, easier to use, extended-release version of cyclosporine, the most common calcineurin inhibitor, into first-in-human trials. If this paper is correct, investors should probably consider throwing money at me.
I don't think anyone needs credentials to have an interesting idea, but it's laughable that someone with no lab or research or business experience is an actual player in this space. I guess people can invest in him if they want. The idea that he's fundraising for human trials is laughable.